U.S. Markets open in 3 hrs 52 mins
  • S&P Futures

    3,698.00
    +28.00 (+0.76%)
     
  • Dow Futures

    29,506.00
    +163.00 (+0.56%)
     
  • Nasdaq Futures

    11,424.75
    +108.50 (+0.96%)
     
  • Russell 2000 Futures

    1,677.10
    +14.60 (+0.88%)
     
  • Crude Oil

    77.57
    +0.86 (+1.12%)
     
  • Gold

    1,641.40
    +8.00 (+0.49%)
     
  • Silver

    18.47
    +0.06 (+0.35%)
     
  • EUR/USD

    0.9618
    +0.0006 (+0.0673%)
     
  • 10-Yr Bond

    3.8780
    0.0000 (0.00%)
     
  • Vix

    31.34
    +1.42 (+4.75%)
     
  • GBP/USD

    1.0785
    +0.0102 (+0.9512%)
     
  • USD/JPY

    144.4620
    -0.2180 (-0.1507%)
     
  • BTC-USD

    20,152.65
    +983.76 (+5.13%)
     
  • CMC Crypto 200

    460.17
    +27.07 (+6.25%)
     
  • FTSE 100

    7,006.58
    -14.37 (-0.20%)
     
  • Nikkei 225

    26,571.87
    +140.32 (+0.53%)
     

Aptinyx to Present at the SVB Leerink 11th Annual Global Healthcare Conference

·1 min read

EVANSTON, Ill., February 08, 2022--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Andy Kidd, M.D., president & chief executive officer, will participate in a virtual fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on Thursday, February 17, 2022 at 10:40 a.m. ET.

A live webcast of the fireside chat will be available to view on the "Events and Presentations" page in the "Investors & Media" section of Aptinyx’s website at https://ir.aptinyx.com and will be archived on Aptinyx’s website for 30 days following the event.

About Aptinyx

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.

Source: Aptinyx Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220208005534/en/

Contacts

Investor and Media Contact:
Patrick Flavin
Aptinyx Inc.
ir@aptinyx.com or corporate@aptinyx.com
847-871-0377